SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BBIO reported Q3 2026 results. The stock moved +6.0% on the print.
BBIOearnings

BridgeBio Pharma, Inc. (BBIO) Q3 FY2026 earnings

October 30, 2026 · SharpeIQ Research Desk

Reported results

  • Total net revenues for the third quarter of 2026 were $353.2 million, compared to $120.7 million for the third quarter of 2025.
  • U.S. Attruby net product revenue reached $253.2 million in the third quarter of 2026.
  • GAAP loss from operations was $11.6 million for the third quarter of 2026.
  • GAAP net loss attributable to common stockholders was $83.0 million for the third quarter of 2026, compared to $182.7 million for the third quarter of 2025.
  • GAAP basic and diluted net loss per share attributable to common stockholders was $0.42 for the third quarter of 2026, compared to $0.95 for the third quarter of 2025.
  • Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026.

Price and volatility reaction

The stock moved +6.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +0.8 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release70.732026-10-29
Close after release74.952026-10-30
Realised move+6.0%close to close
30d ATM IV change+0.8 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →